TM
TMO.US Thermo Fisher Scientific Inc
- Market cap
- USD 257B
- P/E
- 36.5x
- P/B
- 4.65x
- ROE
- 12.4%
- Dividend yield
- 0.25%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is TMO.US undervalued?
Graham numberTMO.US trades 174.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Thermo Fisher Scientific Inc fundamental analysis
No fundamental analysis for Thermo Fisher Scientific Inc yet.
Thermo Fisher Scientific Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of …
Full company profileThermo Fisher Scientific Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Thermo Fisher Scientific Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 18.3B | 20.9B | 24.4B | 25.5B | 32.2B | 39.2B | 44.9B | 42.9B | 42.9B | 44.6B | 46.8B |
| Gross Profit | 8.58B | 9.68B | 11.0B | 11.3B | 16.0B | 19.6B | 19.0B | 17.6B | 17.7B | 18.2B | 19.5B |
| Operating Income | 2.86B | 3.27B | 3.87B | 4.26B | 7.90B | 10.3B | 8.53B | 6.86B | 7.66B | 8.11B | 8.28B |
| EBITDA | 4.25B | 5.05B | 6.20B | 7.02B | 10.1B | 12.0B | 11.9B | 6.86B | 11.8B | 11.5B | 10.7B |
| Net Income | 2.02B | 2.23B | 2.94B | 3.70B | 6.38B | 7.73B | 6.95B | 6.00B | 6.34B | 6.74B | 6.81B |
| EPS | 5.09 | 5.59 | 7.24 | 9.17 | 16 | 19 | 18 | 15 | 17 | 18 | 18 |
| Balance Sheet | |||||||||||
| Total Assets | 45.9B | 56.7B | 56.2B | 58.4B | 69.1B | 95.1B | 97.2B | 98.7B | 97.3B | 110B | 114B |
| Total Liabilities | 24.4B | 31.3B | 28.6B | 28.7B | 34.5B | 54.1B | 53.0B | 51.9B | 47.7B | 56.8B | 59.5B |
| Shareholders' Equity | 21.5B | 25.4B | 27.6B | 29.7B | 34.5B | 40.8B | 44.0B | 46.7B | 49.6B | 53.4B | 54.8B |
| Cash & Short-term Investments | 786M | 1.34B | 2.10B | 2.40B | 10.3B | 4.48B | 8.52B | 8.08B | 5.58B | 10.1B | 6.06B |
| Total Debt | 16.6B | 21.0B | 19.0B | 18.5B | 22.5B | 36.3B | 36.1B | 36.4B | 32.8B | 39.4B | 41.4B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 3.16B | 4.01B | 4.54B | 4.97B | 8.29B | 9.54B | 9.15B | 8.41B | 8.67B | 7.82B | 7.82B |
| Capital Expenditure | 444M | 508M | 758M | 926M | 1.47B | 2.52B | 2.24B | 1.48B | 1.40B | 1.53B | 1.68B |
| Free Cash Flow | 2.71B | 3.50B | 3.79B | 4.05B | 6.82B | 7.02B | 6.91B | 6.93B | 7.27B | 6.29B | 6.14B |
| Ratios | |||||||||||
| ROE | 9.4% | 8.8% | 10.7% | 12.5% | 18.5% | 18.9% | 15.8% | 12.8% | 12.8% | 12.6% | 12.4% |
| ROA | 4.4% | 3.9% | 5.2% | 6.3% | 9.2% | 8.1% | 7.2% | 6.1% | 6.5% | 6.1% | 6.0% |
| Net Profit Margin | 11.1% | 10.6% | 12.1% | 14.5% | 19.8% | 19.7% | 15.5% | 14.0% | 14.8% | 15.1% | 14.5% |
| Debt to Equity | 0.77x | 0.83x | 0.69x | 0.62x | 0.65x | 0.89x | 0.82x | 0.78x | 0.66x | 0.74x | 0.76x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Thermo Fisher Scientific Inc dividends
- Dividend yield
- 0.25%
- Forward dividend
- 1.88 USD
- Payout ratio
- 9.4%
- Ex-dividend date
- Dec 15, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 636M | 1.69 | 9.4% |
| 2024 | USD 583M | 1.52 | 9.2% |
| 2023 | USD 523M | 1.35 | 8.7% |
| 2022 | USD 455M | 1.15 | 6.5% |
| 2021 | USD 395M | 0.99 | 5.1% |
| 2020 | USD 337M | 0.84 | 5.3% |
| 2019 | USD 297M | 0.74 | 8.0% |
| 2018 | USD 266M | 0.66 | 9.1% |
| 2017 | USD 237M | 0.60 | 10.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 3:2 on Jun 6, 1996.
Who owns Thermo Fisher Scientific Inc
- Insiders 0.22%
- Institutions 96.16%
- Public & others 3.62%
- Shares outstanding 371M
- Free float 370M
Top funds holding TMO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 11.7M | 3.17% | -0.63% | Sep 2026 |
| Vanguard 500 Index Investor | 9.71M | 2.62% | -1.62% | Sep 2026 |
| iShares Core S&P 500 ETF | 4.93M | 1.33% | +0.17% | Oct 2026 |
| Fidelity Contrafund | 4.92M | 1.33% | +19.30% | Sep 2026 |
| Fidelity 500 Index | 4.81M | 1.30% | -0.39% | Sep 2026 |
| State Street® SPDR® S&P 500® ETF | 4.51M | 1.22% | -0.25% | Oct 2026 |
| Vanguard MStar Value Index Investor | 3.52M | 0.95% | -0.87% | Sep 2026 |
| State Street®HlthCrSelSectSPDR®ETF | 2.71M | 0.73% | +0.88% | Oct 2026 |
| Vanguard Institutional Index I | 1.96M | 0.53% | -1.54% | Sep 2026 |
| Dodge & Cox Stock I | 1.93M | 0.52% | -6.57% | Sep 2026 |
| American Funds American Balanced A | 1.77M | 0.48% | +37.37% | Sep 2026 |
| Putnam Large Cap Value A | 1.73M | 0.47% | 0.00% | Sep 2026 |
| Strategic Advisers Fidelity US TtlStk | 1.64M | 0.44% | +2.02% | Sep 2026 |
| American Funds Fundamental Invs A | 1.59M | 0.43% | +19.18% | Sep 2026 |
| American Funds Growth Fd of Amer A | 1.50M | 0.41% | -9.31% | Sep 2026 |
| American Funds New Perspective A | 1.47M | 0.40% | 0.00% | Sep 2026 |
| American Funds Invmt Co of Amer A | 1.35M | 0.36% | +2.86% | Sep 2026 |
| American Funds Washington Mutual A | 1.19M | 0.32% | 0.00% | Sep 2026 |
| Vanguard PRIMECAP Inv | 1.16M | 0.31% | -5.67% | Sep 2026 |
| Vanguard Health Care ETF | 1.14M | 0.31% | +0.13% | Sep 2026 |
Top institutions holding TMO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 30.9M | 8.35% | +1.62% | Jun 2026 |
| Vanguard Capital Management, LLC | 24.3M | 6.55% | -0.02% | Jun 2026 |
| State Street Corp | 16.8M | 4.54% | +0.56% | Jun 2026 |
| FMR Inc | 14.1M | 3.80% | +30.70% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 10.8M | 2.90% | -0.92% | Jun 2026 |
| JPMorgan Chase & Co | 8.50M | 2.30% | +25.14% | Jun 2026 |
| Geode Capital Management, LLC | 8.38M | 2.26% | -0.30% | Jun 2026 |
| Franklin Templeton Inc | 7.27M | 1.96% | +6.73% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 6.23M | 1.68% | +1.02% | Jun 2026 |
| Capital World Investors | 6.20M | 1.67% | -6.78% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 5.12M | 1.38% | -18.99% | Jun 2026 |
| NORGES BANK | 5.09M | 1.37% | -4.05% | Jun 2026 |
| Capital Research Global Investors | 4.19M | 1.13% | +0.98% | Sep 2026 |
| Bank of New York Mellon Corp | 3.94M | 1.06% | +4.56% | Jun 2026 |
| Bank of America Corp | 3.90M | 1.05% | -29.60% | Jun 2026 |
| Royal Bank of Canada | 3.43M | 0.93% | -12.34% | Jun 2026 |
| Northern Trust Corp | 3.33M | 0.90% | -2.54% | Jun 2026 |
| Capital Research & Mgmt Co - Division 3 | 3.14M | 0.85% | -1.31% | Sep 2026 |
| Charles Schwab Investment Management Inc | 3.11M | 0.84% | +6.12% | Jun 2026 |
| Dodge & Cox | 3.05M | 0.82% | +11,767.36% | Jun 2026 |
Thermo Fisher Scientific Inc company profile
- Company name
- Thermo Fisher Scientific Inc
- Ticker
- TMO.US
- Exchange
- USA Stocks
- Listed since
- Jan 13, 1978
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 125,000
- Fiscal year end
- December
- Address
- 168 Third Avenue, Waltham, MA, United States, 02451
- Phone
- 781 622 1000
- Website
- thermofisher.com
About Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Thermo Fisher Scientific Inc management
10- Mr. Marc N. CasperChairman & CEO · born 1968
- Mr. Gianluca PettitiPresident, COO & President of Products and Technologies · born 1979
- Mr. James R. MeyerSenior VP & CFO · born 1979
- Mr. Joseph R. HolmesVP & Chief Accounting Officer · born 1980
- Mr. Ryan J. SnyderSenior VP & Chief Information Officer
- Dr. Karen E. Nelson Ph.D.Chief Scientific Officer
- Mr. Rafael TejadaVice President of Investor Relations
- Mr. Thomas Bailey Shropshire Jr.Senior VP and General Counsel
- Ms. Sandy B. PoundVP & Chief Communications Officer
- Mr. Alan J. MalusSenior Vice President of Strategy & Corporate Development · born 1960